Center for Drug Evaluation and Research Director Janet Woodcock sounded an alarm about FDA's biosimilar program, warning it could "explode" from a potentially overwhelming workload and insufficient resources.
It suggests that user fees may not be enough to support the biosimilar program, which already has proven much more popular and labor intensive than expected.